Antonio Calles Blanco

15PUBLICATIONS
144CO-AUTHORS
Molecular targetsLiquid biopsiesCancer therapy (excl. chemotherapy and radiation therapy)Predictive and prognostic markersApplied immunology (incl. antibody engineering, xenotransplantation and t-cell therapies)
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (15)

|Oct 14, 2026
Second- and third-line outcomes after selective RET inhibitor failure in RET fusion-positive metastatic lung cancer: A real-world analysis from the RET-MAP registry.

|Aug 17, 2026
Therapy for Stage IV Non-Small Cell Lung Cancer With Driver Alterations: ASCO Living Guideline, Version 2026.3.3.

|Nov 27, 2025
Real-World Data of First-Line Cemiplimab Monotherapy for Metastatic Non-Small Cell Lung Cancer (NSCLC) with PD-L1 Expression ≥ 50%: A National Spanish Multicentric Cohort (CEMI-SPA Study).

Silvia Masini, Monica Antoñanzas Basa, Antonio Calles

|Dec 05, 2024
Unveiling the Mechanism of Lurbinectedin's Action and Its Potential in Combination Therapies in Small Cell Lung Cancer.

Antonio Calles, Emiliano Calvo, Gema Santamaría Nuñez

|Aug 26, 2022
An International Comparison of Presentation, Outcomes and CORONET Predictive Score Performance in Patients with Cancer Presenting with COVID-19 across Different Pandemic Waves.

Oskar Wysocki, Cong Zhou, Jacobo Rogado

|May 24, 2022
Establishment of CORONET, COVID-19 Risk in Oncology Evaluation Tool, to Identify Patients With Cancer at Low Versus High Risk of Severe Complications of COVID-19 Disease On Presentation to Hospital.

Rebecca J Lee, Oskar Wysocki, Cong Zhou

Pageof 3

Frequent Collaborators

2 joint publications

Cong Zhou

2 joint publications

Spyridon Gennatas

2 joint publications

Benjamin Besse

2 joint publications

Rohan Shotton